Abstract | PURPOSE: EXPERIMENTAL DESIGN: RESULTS: Of the 5 evaluable patients vaccinated with unmodified polySA, only 1 mounted an IgM antibody response to polySA. On the other hand, all 6 of the patients vaccinated with NP-polySA produced IgM antibodies to NP-polySA and these cross-reacted with unmodified polySA in all but 1 case. IgG antibodies to NP-polySA were observed in 5 of the patients, but these did not cross-react with polySA. The presence of IgM antibodies reactive with SCLC cell lines was confirmed in this group by flow cytometry. Complement-dependent lysis of tumor cells could not be demonstrated. However, postimmunization sera induced significant bactericidal activity against group B meningococcus when combined with rabbit complement. CONCLUSIONS: Vaccination with NP-polySA-KLH, but not polySA-KLH, resulted in a consistent high titer antibody response. We are now conducting a de-escalation dosing study with NP-polySA-KLH to better assess the immunogenicity, toxicities, and optimal dose of this vaccine. We plan to incorporate this vaccine as a component of a polyvalent vaccine with GM2, fucosylated GM1, and Globo H to target SCLC.
|
Authors | Lee M Krug, Govind Ragupathi, Kenneth K Ng, Chandra Hood, Harold J Jennings, Zhongwu Guo, Mark G Kris, Vincent Miller, Barbara Pizzo, Leslie Tyson, Valerie Baez, Philip O Livingston |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 10
Issue 3
Pg. 916-23
(Feb 01 2004)
ISSN: 1078-0432 [Print] United States |
PMID | 14871967
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Adjuvants, Immunologic
- Antigens, Tumor-Associated, Carbohydrate
- Cancer Vaccines
- Globo-H
- Immunoglobulin G
- Immunoglobulin M
- Saponins
- Sialic Acids
- Vaccines, Conjugate
- globo H-keyhole limpet hemocyanin QS-21 vaccine
- polysialic acid
- G(M2) Ganglioside
- G(M1) Ganglioside
- saponin QA-21V1
- Complement System Proteins
- Hemocyanins
- keyhole-limpet hemocyanin
|
Topics |
- Adjuvants, Immunologic
(pharmacology)
- Aged
- Antigens, Tumor-Associated, Carbohydrate
(metabolism)
- Cancer Vaccines
(therapeutic use)
- Carbohydrate Sequence
- Carcinoma, Small Cell
(therapy)
- Complement System Proteins
- Enzyme-Linked Immunosorbent Assay
- Female
- Flow Cytometry
- G(M1) Ganglioside
(metabolism)
- G(M2) Ganglioside
(metabolism)
- Hemocyanins
(therapeutic use)
- Humans
- Immunoglobulin G
(chemistry)
- Immunoglobulin M
(chemistry)
- Immunotherapy
(methods)
- Lung Neoplasms
(therapy)
- Male
- Middle Aged
- Models, Chemical
- Molecular Sequence Data
- Saponins
(pharmacology)
- Sialic Acids
(therapeutic use)
- Time Factors
- Vaccines, Conjugate
(therapeutic use)
|